For the most part, start-ups begin life with a license to raw technology, at best a couple of compounds in very early development, and little commercial infrastructure. That was not the case with EyeTech Pharmaceuticals Inc. , however, which got its start in large part because it had a development infrastructure, which enabled it to in-license a product from a major biotech company.
Company co-founder David Guyer, MD, a professor of ophthalmology at New York University Medical Center , believed that blocking...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?